Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Indivior Pharmaceuticals, Inc. - Common Stock (NQ:INDV)

32.09 -0.63 (-1.94%)
Streaming Delayed Price Updated: 2:42 PM EST, Mar 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Indivior Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Indivior (INDV) Q4 2025 Earnings Call Transcript ↗
Indivior (INDV) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
Indivior Pharmaceuticals Inc (NASDAQ:INDV) Surpasses Q4 2025 Estimates and Provides Strong 2026 Outlook ↗
Via Chartmill
News headline image
Vistance Networks Stock Up 250%. Here's Why a $40 Million Position Signals a Post-Divestiture Bet ↗
Vistance Networks delivers connectivity and network solutions for telecom, data centers, and enterprise clients worldwide. 
Via The Motley Fool
News headline image
Array Stock Down 25%, But This $17.3 Million Buy Signals Confidence Amid Big Revenue Growth ↗
Array Digital Infrastructure delivers wireless services and device sales to consumers, businesses, and government clients nationwide. 
Via The Motley Fool
Topics Regulatory Compliance
INDIVIOR PHARMACEUTICALS INC (NASDAQ:INDV) Presents a High-Growth Momentum and Technical Setup Case ↗
Via Chartmill
INDIVIOR PHARMACEUTICALS INC (NASDAQ:INDV) Presents a High-Growth Momentum Breakout Setup ↗
Via Chartmill
News headline image
Enviri Stock Up 120% as $43 Million Buy Makes It a Top Holding in This Portfolio ↗
Enviri delivers environmental and specialty waste solutions for industrial clients through long-term contracts and value-added products. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Integer Stock Down 38%, but One Fund Just Bet $40 Million on a Turnaround ↗
Integer Holdings supplies medical device components and finished products to major OEMs in cardiac, neuro, and surgical markets. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Mangrove Partners Loads Up Flywire With 2.9 Million Shares ↗
The new holding places Flywire outside the fund’s top five positions. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Earnings Scheduled For October 30, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For July 31, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For April 24, 2025 ↗
 
Via Benzinga
News headline image
A Look at Indivior's Upcoming Earnings Report ↗
 
Via Benzinga
News headline image
INDIVIOR PLC (NASDAQ:INDV) Presents a High-Growth Momentum and Technical Breakout Setup ↗
INDIVIOR stock combines high-growth earnings momentum with a strong technical uptrend and a current bull flag setup for a potential breakout. 
Via Chartmill
News headline image
This Biotech Is Up 194% in a Year but One Investor Took Millions Off the Table ↗
When a biotech rallies nearly 200% and still gets trimmed, the real story likely isn’t about fear or a loss of conviction. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Bardin Hill Dumps 349,000 Shares of Frontier Communicaitons Stock Worth $12.7 Million ↗
The position previously accounted for 7.48% of fund AUM as of the prior quarter. 
Via The Motley Fool
Topics Initial Public Offering Regulatory Compliance
News headline image
Millrose Properties Stock Has Surged 48% Since February Debut — So Why Did One Investor Sell a $23 Million Stake? ↗
A newly public real-estate platform is putting up numbers that look far more seasoned than its age. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why One Investor Bought $67.5 Million in Array Digital Infrastructure Stock ↗
One fund just made a bold bet on a telecom stock undergoing a big transformation 
Via The Motley Fool
News headline image
Why One Value Fund Has a $101 Million Bet on Indivior Stock Amid a 212% Surge ↗
This fund just doubled down on a stock that’s suddenly delivering the earnings momentum it’s promised for years. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why One Value Fund Just Bought $30 Million of a Diagnostics Stock Down 90% From Pandemic-Era Highs ↗
A beaten-down diagnostics stock is quietly tightening margins and drawing fresh institutional conviction—here’s what that means for long-term investors. 
Via The Motley Fool
News headline image
The Remitly Reassessment: What Divisadero’s 95 Million Exit Tells Us About Digital Money Movement ↗
Divisadero’s $95 million selloff sends a message about where Remitly stands in the shifting economics of global money movement. Here’s what that signal may mean for long-term investors. 
Via The Motley Fool
News headline image
Here's Why Indivior Stock Soared 15% Today ↗
This company is accelerating sales growth in its key prescription medication. 
Via The Motley Fool
News headline image
INDIVIOR PLC (NASDAQ:INDV) Shows Top Technical and Setup Ratings for Potential Breakout ↗
INDIVIOR (INDV) shows strong technicals with a perfect 10 rating and a 9 setup score, signaling a potential breakout above $25.20 resistance. 
Via Chartmill
News headline image
This Palvella Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗
 
Via Benzinga
News headline image
Indivior (INDV) Q2 EPS Jumps 104% ↗
Via The Motley Fool
News headline image
Roblox, Carvana, eBay, C.H. Robinson Worldwide, Huntington Ingalls Industries And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
Indivior (INDV) Q1 2025 Earnings Call ↗
Via The Motley Fool
News headline image
Indivior PLC: Is This Deeply Undervalued Stock A Hidden Gem? ↗
With a strong position in a niche yet vital therapeutic area, Indivior PLC benefits from durable brand equity, a specialized distribution network, and a long runway for product innovation. 
Via Talk Markets
Topics Stocks / Equities
News headline image
European Addiction-Focused Indivior Stock Falls As Drugmaker Warns Lower Revenues In 2025 Despite Q4 Earnings Beat ↗
Indivior's 2025 outlook missed estimates, citing Suboxone sales erosion. The company plans $100 million in cost cuts, with $50M reinvested in Sublocade. 
Via Benzinga
News headline image
Stay updated with the stocks that are on the move in today's pre-market session. ↗
As we await the opening of the US market on Thursday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment. 
Via Chartmill
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.